Reverse mergers attract top-tier biotechs in sluggish IPO market.
Lawrence
Stacy
S
D001709:Biotechnology / Q000458:organization & administration*; D002202:Capital Financing / Q000458:organization & administration*; D007221:Industry / Q000458:organization & administration*; D007373:Interinstitutional Relations; D010067:Ownership / Q000458:organization & administration*; D014481:United States